Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: Results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC).

[1]  Eric A. Miller,et al.  Extended follow‐up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial , 2018, BJU international.

[2]  E. Feuer,et al.  The efficacy of prostate‐specific antigen screening: Impact of key components in the ERSPC and PLCO trials , 2018, Cancer.

[3]  J. Sterne,et al.  Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial , 2018, JAMA.

[4]  David Gillatt,et al.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. , 2017, The New England journal of medicine.

[5]  T. Tammela,et al.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up , 2014, The Lancet.

[6]  L. Remontet,et al.  Cancer incidence and mortality in France over the 1980-2012 period: solid tumors. , 2014, Revue d'epidemiologie et de sante publique.

[7]  B. G. Blijenberg,et al.  Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. , 2013, European urology.

[8]  T. Tammela,et al.  Prostate cancer mortality in the Finnish randomized screening trial. , 2013, Journal of the National Cancer Institute.

[9]  B. G. Blijenberg,et al.  Prostate-cancer mortality at 11 years of follow-up. , 2012, The New England journal of medicine.

[10]  J. Gohagan,et al.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. , 2012, Journal of the National Cancer Institute.

[11]  J. Ferlay,et al.  Prostate cancer incidence and mortality trends in 37 European countries: an overview. , 2010, European journal of cancer.

[12]  Erik Holmberg,et al.  Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. , 2010, The Lancet. Oncology.

[13]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[14]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[15]  M. Roobol,et al.  The story of the European Randomized Study of Screening for Prostate Cancer , 2003, BJU international.

[16]  A. Villers,et al.  ERSPC: features and preliminary results of France , 2003, BJU international.

[17]  A. Auvinen,et al.  Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening , 2003, BJU international.

[18]  A. Méjean,et al.  Dépistage du cancer de la prostate , 2003 .

[19]  H. D. de Koning,et al.  Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European randomised screening for prostate cancer (ERSPC) trial , 2002, International journal of cancer.

[20]  N Segnan,et al.  Adjusting for non-compliance and contamination in randomized clinical trials. , 1997, Statistics in medicine.

[21]  Shandra S. Wilson.  Prostate cancer screening , 2005, Comprehensive therapy.